Skip to main content

Menu

Pioneering the next generation of precision oncology

About Us

Scorpion is a pioneering clinical-stage oncology company redefining the frontier of precision medicine to deliver transformational therapies for larger populations of patients with cancer

Cancer has always been an elusive foe, capable of evolving to evade our attempts at eradication. From genetic mutations and chromosomal instabilities to changes in key enzymes and proteins, the drivers that tumor cells rely on to survive can be exploited for therapeutic benefit – an insight that led to the first successful precision oncology therapies more than 20 years ago.

We’ve come a long way from the early days of cancer therapies. Yet, the full promise of personalized medicine has not yet been realized, as only a small number of these drivers have been successfully targeted and treated with precision therapies.

Currently, about 14% of all patients with cancer are eligible for existing precision oncology therapies and only 7% realize clinical benefits.1
We aim to change that.

Our Approach

Aiming to deliver a fast, precise and lethal strike at cancer’s unique drivers

Before we launch a program against a new, high-value target, we always ask ourselves:

 

  • Can selective target inhibition improve patients’ survival or quality of life beyond what’s possible with the current standard treatment?
  • Can the target be dosed to achieve therapeutic effects without causing unmanageable and potentially toxic side effects?
  • Can inhibiting the target offer benefits as part of combination therapy?
Our Pipeline

Why our work matters

We are developing drugs specifically designed to interact with validated cancer targets with greater selectivity and optimized pharmaceutical properties to improve their safety and efficacy.

Array

Meet our
leadership team

Our world-class team is comprised of experts in cancer biology, medicinal chemistry, next-generation chemical proteomics, computational chemistry and molecular biophysics, machine learning, and drug development. Together, they have architected a new and innovative approach to target and drug discovery.

Our Team

News

All News

Growing a thriving culture

The work environment we have created is as important to us as our science. We are looking for team members who share our cultural commitments.

JOIN US